HS-10365 is a RET tyrosine kinase inhibitor developed for non-small cell lung cancer by Hansen Pharmaceutical.[1][2]
References edit
- ^ Lu, Shun; Wang, Qiming; Wu, Lin; Xing, Ligang; Li, Yintao; Han, Liang; Dong, Xiaorong; Wei, Hongying; Xu, Wen; Li, Chuan; Yang, Liuqing; Wu, Qiong (14 April 2023). "Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients". Cancer Research. 83 (8_Supplement): CT201–CT201. doi:10.1158/1538-7445.AM2023-CT201.
- ^ Shabbir, Arafat; Kojadinovic, Arsenije; Shafiq, Tabinda; Mundi, Prabhjot S. (January 2023). "Targeting RET alterations in cancer: Recent progress and future directions". Critical Reviews in Oncology/Hematology. 181: 103882. doi:10.1016/j.critrevonc.2022.103882.